Conversion surgery for unresectable pancreatic cancer with liver metastasis can significantly improve survival for select patients.

• In a study of 90 patients, overall survival after conversion surgery was 39.7 months, with earlier treatment yielding 53.1 months from initial diagnosis.
• Preoperative normalization of CA 19-9 and negative lymph node metastasis were key factors linked to better outcomes.

Selecting patients who respond positively to chemotherapy for conversion surgery may enhance treatment success.